|Videos|December 29, 2022

Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

Author(s)Ruben Mesa, M.D., Rami S. Komrokji, M.D.

Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Photo of Dr. Prithviraj Bose

Expert Highlights Importance of Understanding Myelofibrosis Treatments

ByDr. Prithviraj Bose

September 17th 2025

Photo of Dr. Prithviraj Bose

How to Individually Tailor Myelofibrosis Treatment Options

September 16th 2025

For patients with myelofibrosis, there is a risk of non-melanoma skin cancer: © stock.adobe.com.

Jakafi for Myelofibrosis Associated With Skin Cancer, Shingles Risk

September 16th 2025

Image of FDA offices

Rusfertide Earns Breakthrough Therapy Designation in Polycythemia Vera

August 25th 2025

Clinical Trial Corner image

Various Clinical Trials in Oncology Announce Key Trial Milestones

August 22nd 2025

Trending on CURE

New Strategy May Prevent Breast Cancer Relapse

FDA Approves Enoby and Xtrenbo Biosimilars for Bone Health and Cancer Care

Understanding the Evolving Role of a Pathologist in Lung Cancer Care

All FDA Oncology Approvals From September 2025

Positive Experience With TAR-200 for Recurrent Bladder Cancer

© 2025 MJH Life Sciences^®

All rights reserved.